Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3
Johnson & Johnson today said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.
The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Related News Articles
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…